End-of-Malaria-small.jpg
Dr. Hoffman.jpg
Screen Shot 2014-01-30 at 6.26.33 PM.png
Screen Shot 2014-02-10 at 12.44.55 PM.png
IMG_6101.jpg
End-of-Malaria-small.jpg

End of Malaria


SCROLL DOWN

End of Malaria


 

Over the past decade, we at Sanaria, a biotech company in Rockville, MD, developed a malaria vaccine called the PfSPZ Vaccine. 

Until now, no vaccine has ever proven sufficiently effective in protecting against the malaria parasite. During a clinical trial of our PfSPZ Vaccine, as reported in August 2013, for the first time in history a malaria vaccine protected all subjects of one group against malaria.

To mass produce the vaccine and make it affordable to those who need it most, we need your help to build a mosquito dissecting robot to help automate our vaccine manufacturing process.

 

Please support our campaign on Indiegogo, and become a part of the movement to end malaria!

 

THE GOAL

Campaign Launch Date: Tuesday, May 6, 2014

 

FEATURED IN

A Goal to Combat Malaria With the Help of a Robot

Robot May Help Fight Malaria

The Robot That Could Kill Malaria

Wanted - A Bug Spit Robot

How a Crowd Funded Robot Could Finally End Malaria

Crowdfunding to Combat Malaria

Robot Combats Malaria with World's First Vaccine

Biotech Form Aims to Automate Malaria Vaccine Production

Malarial Vaccine Firm Seeks Crowdfunding for Robo-Saliva Surgeon

DC Based IndieGoGo Campaign Calls Upon Harvard Robotics Team to Help Cure Malaria

Sanaria wins Vaccine Industry Excellence Award for the best Prophylactic Vaccine at the 2014 World Vaccine Congress. 

Click here to access the press release, malaria facts, FAQs, contact information, and high resolution images. 


MALARIA

 

In 1977 a vaccine led to the eradication of smallpox from the world.

In 1988 two vaccines were deployed to facilitate the elimination of polio which should be eradicated in the next few years.

Today vaccines have nearly led to the elimination of other diseases such as tetanus and measles.

But not malaria.

 


 

Unlike diseases caused by bacteria or viruses, malaria is caused by a complex parasite that grows within the mosquito. We have learned after many years of hard work that this complex parasite requires a relatively simple vaccine. The best way to protect people from malaria is to give them a shot of the weakened malaria parasites themselves – similar to the smallpox vaccine.

Our malaria vaccine comes from within the mosquito itself.

Growing malaria parasites in the mosquito to create the vaccine was an insurmountable challenge to most in the scientific community.

But not to Dr. Stephen Hoffman and Dr. Kim Lee Sim.

 
Dr. Hoffman.jpg

The Vaccine


SCROLL DOWN

The Vaccine


In 2003, Dr. Stephen Hoffman and Dr. Kim Lee Sim started Sanaria at the kitchen table of their home. 

Now nearly 50 scientists, researchers, and innovators have joined the Sanaria team.

Today we have developed the world's first malaria vaccine to show 100% protection. 

Watch the news break on CNN

Watch the Sanaria team watch the news!

Here's how we did it.


 

With grant funding from the National Institute of Allergy and Infectious DiseasesNational Institutes of Health, the Bill & Melinda Gates Foundation through the PATH Malaria Vaccine Initiative, and the Department of Defense, we developed our manufacturing process and built our clinical manufacturing facility and insectary in Rockville, MD.

We grow malaria parasites in mosquitoes to use in the manufacturing process for PfSPZ Vaccine. We weaken the parasites to be used in the vaccine, which elicits an immune response to protect the human recipient.

In a nutshell, we extract the parasites from the mosquitoes, purify them, vial them, and the vaccine is ready to go.

 
Disection.jpg

Our manufacturing process is good, but good is not good enough. 

Screen Shot 2014-01-30 at 6.26.33 PM.png

The Current Method


SCROLL DOWN

The Current Method


 

Our dedicated team extracts the salivary glands of mosquitoes that contain the irradiated malaria parasites - a process we do by hand dissection.

We process these parasites that ultimately become our vaccine.  

Using this process, the vaccine was 100% protective in the group that received the highest dose in a recent clinical trial.

The current method has achieved great success and now we need to take the next steps.

 

It is now time to develop better methods to mass produce our vaccine.

That's why we started working with Harvard University's Biorobotics Lab

Screen Shot 2014-02-10 at 12.44.55 PM.png

SporoBot™


SCROLL DOWN

SporoBot™


This campaign is to fund SporoBot™ - a mosquito dissecting robot.

 

Working with Harvard University's Biorobotics Lab, we're developing a robot that can automate our current hand dissection process. We estimate one SporoBot™ will be able to produce vaccine at 20 - 30 times our current efficiency.

This breakthrough will allow us to make vaccines at 

LOWER COST

&

GREATER EFFICIENCY

so we can deliver the vaccine to those who need it the most

and eliminate malaria.

 
Current v. Sporobot wide.jpg

 

We've built the parts, we've demonstrated they work, now we need to assemble SporoBot™ into a working prototype. And for this, we need your help. 

 
IMG_6101.jpg

The Movement


SCROLL DOWN

The Movement


 

Currently, the funds we receive from grants and awards support our clinical trials and specific research projects at home and overseas in Africa and Europe. To seek adequate funding from these sources specifically for SporoBot™ could take years, but we believe in the power of all of us to help us act now to achieve our goals quickly!

 

That's why from May 6th to June 6th, we turn to you for support.

Help us raise $250,000 in 30 days!

 
 

Most of the people who will directly benefit from our vaccine do not have the funds or access to participate in this campaign. 

Please consider pledging your support for those who need this vaccine the most and have the least. 

Together we can put an end to malaria. 

 

Questions?